Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2926941 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL9954583 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL9955207 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL30492127 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL6263078 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL7530714 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL707486 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL2904077 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL3948914 | 1.00 | ACE2 (0.46) | ACE2GPR84FFAR1MAPTLCK | |
| SCHEMBL8882093 | 0.98 | ACE2 (0.43) | ACE2GPR84FFAR1MAPTLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11123268-B2 | Tablet form of cosmetic composition obtained by direct tableting without molding plate and method for preparing same | COSMAX, INC. (KR) | 2021-09-21 | — | — | US | disclosed |
| US-20200163845-A1 | Tablet Form Of Cosmetic Composition Obtained By Direct Tableting Without Molding Plate And Method For Preparing Same | COSMAX, INC. (KR) | 2020-05-28 | — | — | US | disclosed |
| US-20070025942-A1 | Clear gel antiperspirant or deodorant compositions and related methods | CITICORP USA, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070025942-A1 | Clear gel antiperspirant or deodorant compositions and related methods | OPRD1, DRD1, RAB5IF | ACE2 3621/4885GPR84 567/4885FFAR1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.